Thermo Fisher Scientific Inc.is a provider of analytical instruments equipment reagents and consumables software and services for research manufacturing analysis discovery and diagnostics. 1 Month Ago, the stock has been rated as “Buy” from 15 Analysts. NYSE is measured to be 5.05% in conjunction with the 200-Day Simple Moving Average of 13.52%. Mizuho upped their target price on shares of Thermo Fisher Scientific from $150.00 to $160.00 and gave the stock a buy rating in a research report on Monday, April 4th. The lowest analyst target sees the stock at $105 over the same time period. The ratio is positive, as 54 funds sold all Thermo Fisher Scientific Inc. shares owned while 371 reduced positions. The stock has received “OVERWEIGHT” rating after consensus analysis from analysts. Revenues from the Laboratory Products and Services Segment improved 6% to $1.80 billion, while the Specialty Diagnostics Segment recorded 4% revenue growth to $851 million. Finally, Bank of America Corp. reiterated a “buy” rating and set a $163.00 price target on shares of Thermo Fisher Scientific in a report on Wednesday, May 11th.
Advertisement
Thermo Fisher beat the expectations of analysts polled by Thomson Reuters, who forecast $2.01 in per-share earnings, on revenue of $4.5 billion. The company has a market cap of $62.93 billion. The company reported $2.03 earnings per share for the quarter, topping the consensus estimate of $2.01 by $0.02. Leerink Swann reiterated a “buy” rating on shares of Thermo Fisher Scientific in a report on Sunday, May 29th.
“Our collaboration with Thermo Fisher Scientific will enable HBM to meet a critical need in the China market for a series of high accuracy kits created to run on a single CE platform to improve human health outcomes”, said Jianwei Yu, Chairman and CEO of HEALTH BioMed.
Advertisement
The buoyancy in the prospect of Thermo Fisher Scientific, Inc. The shares were sold at an average price of $148.31, for a total transaction of $1,023,339.00. “Underperform” verdict was shared by 0 analyst and “Outperform” recommendation was issued by 7 analyst. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The Hedge Fund company now holds 170,063 shares of TMO which is valued at $26,681,184. The stock was sold at an average price of $152.84, for a total transaction of $2,292,600.00. The disclosure for this sale can be found here. The group worked out on the stock recommendations given by analysts in the First Call poll. Gulf International Bank UK Ltd boosted its position in shares of Thermo Fisher Scientific by 2.4% in the fourth quarter. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
